Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum GlobeNewswire August 05, 2025 Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year. Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew […]

Amwell(R) Announces Results for Second Quarter 2025 GlobeNewswire August 05, 2025 BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) — Amwell(R) (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30. The company's second quarter earnings report may be viewed at investors.amwell.com. Amwell will

https://mma.prnewswire.com/media/1871430/Revolve_Group_Logo.jpg Revolve Group, Inc. (NYSE: RVLV), the next-generation fashion retailer for Millennial and Generation Z consumers, today announced financial results for the second quarter ended June 30, 2025. Co-Founder and Co-CEO Commentary “We delivered strong second quarter results, highlighted by 9% growth in net sales year-over-year, 10% growth in operating income year-over-year, our highest Adjusted

NASHVILLE, TN / ACCESS Newswire / August 5, 2025 / First Acceptance Corporation (OTCQX:FACO) today reported its financial results for the quarter ended June 30, 2025. A quarterly report can be found at www.otcmarkets.com/stock/FACO/disclosure. Income before income taxes, for the three months ended June 30, 2025 was $10.1 million, compared with $8.1 million for the

(NYSE:CWEN),(NYSE:CWEN.C),(NYSE:CWEN-C),(NYSE:CWEN.A),(NYSE:CWEN-A), Repowering program advancing with Goat Mountain commercialized for 2027 and Mt. Storm on track Sponsor-enabled growth advancing with 2025/2026 COD program now over 1.6 GW including new offer from Clearway Group to invest in 291 MW Western states storage portfolio Third party acquisitions also continuing with closing of previously announced Catalina Solar project Updating

Clearway Energy, Inc. Reports Second Quarter 2025 Financial Results GlobeNewswire August 05, 2025 Repowering program advancing with Goat Mountain commercialized for 2027 and Mt. Storm on track Sponsor-enabled growth advancing with 2025/2026 COD program now over 1.6 GW including new offer from Clearway Group to invest in 291 MW Western states storage portfolio Third party

(NasdaqGM:GUTS), Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse events to date New real-world findings are consistent with prior two-year clinical data from studies conducted outside the United States,

(NASDAQ:DERM),(NASDAQ:FBIO), SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2025

(NASDAQ:GO), EMERYVILLE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — Grocery Outlet Holding Corp. (NASDAQ: GO) (“Grocery Outlet,” the “Company,” “we” or “our”) today announced financial results for the second quarter of fiscal 2025 ended June 28, 2025. Highlights for Second Quarter Fiscal 2025 as compared to Second Quarter Fiscal 2024: Net sales increased by 4.5%

Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic (“PK”) profiles supporting quarterly or biannual dosing, and full TL1A engagement through up to 20 weeks of follow-up Initiated Phase 2 SKYLINE-UC platform study, evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis (“UC”) On